Skip to main page content
Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

My NCBI Filters
Text availability
Article attribute
Article type
Publication date

Search Results

315 results
Filters applied: . Clear all Results are displayed in a computed author sort order. Results by year timeline is unavailable
Page 1
Guidelines for the definition of time-to-event end points in renal cell cancer clinical trials: results of the DATECAN project†.
Kramar A, Negrier S, Sylvester R, Joniau S, Mulders P, Powles T, Bex A, Bonnetain F, Bossi A, Bracarda S, Bukowski R, Catto J, Choueiri TK, Crabb S, Eisen T, El Demery M, Fitzpatrick J, Flamand V, Goebell PJ, Gravis G, Houédé N, Jacqmin D, Kaplan R, Malavaud B, Massard C, Melichar B, Mourey L, Nathan P, Pasquier D, Porta C, Pouessel D, Quinn D, Ravaud A, Rolland F, Schmidinger M, Tombal B, Tosi D, Vauleon E, Volpe A, Wolter P, Escudier B, Filleron T; DATECAN Renal Cancer group. Kramar A, et al. Among authors: bukowski r. Ann Oncol. 2015 Dec;26(12):2392-8. doi: 10.1093/annonc/mdv380. Epub 2015 Sep 14. Ann Oncol. 2015. PMID: 26371288 Review.
Final results from the large sunitinib global expanded-access trial in metastatic renal cell carcinoma.
Gore ME, Szczylik C, Porta C, Bracarda S, Bjarnason GA, Oudard S, Lee SH, Haanen J, Castellano D, Vrdoljak E, Schöffski P, Mainwaring P, Hawkins RE, Crinò L, Kim TM, Carteni G, Eberhardt WE, Zhang K, Fly K, Matczak E, Lechuga MJ, Hariharan S, Bukowski R. Gore ME, et al. Among authors: bukowski r. Br J Cancer. 2015 Jun 30;113(1):12-9. doi: 10.1038/bjc.2015.196. Epub 2015 Jun 18. Br J Cancer. 2015. PMID: 26086878 Free PMC article.
Sunitinib and sorafenib in metastatic renal cell carcinoma patients with renal insufficiency.
Khan G, Golshayan A, Elson P, Wood L, Garcia J, Bukowski R, Rini B. Khan G, et al. Among authors: bukowski r. Ann Oncol. 2010 Aug;21(8):1618-1622. doi: 10.1093/annonc/mdp603. Epub 2010 Jan 20. Ann Oncol. 2010. PMID: 20089567
A phase I study of sunitinib plus bevacizumab in advanced solid tumors.
Rini BI, Garcia JA, Cooney MM, Elson P, Tyler A, Beatty K, Bokar J, Mekhail T, Bukowski RM, Budd GT, Triozzi P, Borden E, Ivy P, Chen HX, Dolwati A, Dreicer R. Rini BI, et al. Among authors: bukowski rm. Clin Cancer Res. 2009 Oct 1;15(19):6277-83. doi: 10.1158/1078-0432.CCR-09-0717. Epub 2009 Sep 22. Clin Cancer Res. 2009. PMID: 19773375 Free PMC article. Clinical Trial.
Prognostic factors associated with long-term survival in previously untreated metastatic renal cell carcinoma.
Choueiri TK, Rini B, Garcia JA, Baz RC, Abou-Jawde RM, Thakkar SG, Elson P, Mekhail TM, Zhou M, Bukowski RM. Choueiri TK, et al. Among authors: bukowski rm. Ann Oncol. 2007 Feb;18(2):249-55. doi: 10.1093/annonc/mdl371. Epub 2006 Oct 23. Ann Oncol. 2007. PMID: 17060490
Renal cell carcinoma-derived gangliosides suppress nuclear factor-kappaB activation in T cells.
Uzzo RG, Rayman P, Kolenko V, Clark PE, Cathcart MK, Bloom T, Novick AC, Bukowski RM, Hamilton T, Finke JH. Uzzo RG, et al. Among authors: bukowski rm. J Clin Invest. 1999 Sep;104(6):769-76. doi: 10.1172/JCI6775. J Clin Invest. 1999. PMID: 10491412 Free PMC article.
Tumor-induced sensitivity to apoptosis in T cells from patients with renal cell carcinoma: role of nuclear factor-kappaB suppression.
Finke JH, Rayman P, George R, Tannenbaum CS, Kolenko V, Uzzo R, Novick AC, Bukowski RM. Finke JH, et al. Among authors: bukowski rm. Clin Cancer Res. 2001 Mar;7(3 Suppl):940s-946s. Clin Cancer Res. 2001. PMID: 11300495
Signal transduction abnormalities in T lymphocytes from patients with advanced renal carcinoma: clinical relevance and effects of cytokine therapy.
Bukowski RM, Rayman P, Uzzo R, Bloom T, Sandstrom K, Peereboom D, Olencki T, Budd GT, McLain D, Elson P, Novick A, Finke JH. Bukowski RM, et al. Clin Cancer Res. 1998 Oct;4(10):2337-47. Clin Cancer Res. 1998. PMID: 9796963 Clinical Trial.
315 results
Jump to page